ERBB2 and breast cancer: Hence, many drugs (e.g., monoclonal antibodies, immunoglobulins, and small molecule inhibitors) that can facilitate immune checkpoint inhibition are undergoing clinical trials (e.g., NCT03523572, NCT03125928, NCT03523572) for the treatment of HER2+ BC [96].